Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Everolimus
  • Prostatic Neoplasms, Castration-Resistant
  • Quinazolines
  • Signal Transduction

abstract

  • The combination of gefitinib and everolimus did not result in significant antitumor activity. The induction of PSA in tumors treated with mTOR inhibitors was consistent with preclinical data showing that phosphoinositide 3-kinase (PI3K) pathway signaling feedback inhibits the androgen receptor (AR). This clinical evidence of relief of feedback inhibition promoting enhanced AR activity supports future studies combining PI3K pathway inhibitors and second-generation AR inhibitors in CRPC. Cancer 2015;121:3853-3861. © 2015 American Cancer Society.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4618268

Digital Object Identifier (DOI)

  • 10.1002/cncr.29578

PubMed ID

  • 26178426

Additional Document Info

start page

  • 3853

end page

  • 61

volume

  • 121

number

  • 21